371 related articles for article (PubMed ID: 12857911)
21. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.
Boivin G; Goyette N
Antiviral Res; 2002 Jun; 54(3):143-7. PubMed ID: 12062387
[TBL] [Abstract][Full Text] [Related]
22. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors.
McKimm-Breschkin JL; Sahasrabudhe A; Blick TJ; McDonald M; Colman PM; Hart GJ; Bethell RC; Varghese JN
J Virol; 1998 Mar; 72(3):2456-62. PubMed ID: 9499107
[TBL] [Abstract][Full Text] [Related]
23. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay.
Gubareva LV; Webster RG; Hayden FG
Antiviral Res; 2002 Jan; 53(1):47-61. PubMed ID: 11684315
[TBL] [Abstract][Full Text] [Related]
24. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus.
Abed Y; Goyette N; Boivin G
Antivir Ther; 2004 Aug; 9(4):577-81. PubMed ID: 15456089
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor.
Sidwell RW; Huffman JH; Barnard DL; Bailey KW; Wong MH; Morrison A; Syndergaard T; Kim CU
Antiviral Res; 1998 Feb; 37(2):107-20. PubMed ID: 9588843
[TBL] [Abstract][Full Text] [Related]
26. Treatment of influenza with neuraminidase inhibitors: virological implications.
Roberts NA
Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1895-7. PubMed ID: 11779389
[TBL] [Abstract][Full Text] [Related]
27. Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir.
Wang MZ; Tai CY; Mendel DB
Antimicrob Agents Chemother; 2002 Dec; 46(12):3809-16. PubMed ID: 12435681
[TBL] [Abstract][Full Text] [Related]
28. Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host.
Thompson CI; Barclay WS; Zambon MC
J Antimicrob Chemother; 2004 May; 53(5):759-65. PubMed ID: 15028666
[TBL] [Abstract][Full Text] [Related]
29. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.
Mendel DB; Tai CY; Escarpe PA; Li W; Sidwell RW; Huffman JH; Sweet C; Jakeman KJ; Merson J; Lacy SA; Lew W; Williams MA; Zhang L; Chen MS; Bischofberger N; Kim CU
Antimicrob Agents Chemother; 1998 Mar; 42(3):640-6. PubMed ID: 9517945
[TBL] [Abstract][Full Text] [Related]
30. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en.
Staschke KA; Colacino JM; Baxter AJ; Air GM; Bansal A; Hornback WJ; Munroe JE; Laver WG
Virology; 1995 Dec; 214(2):642-6. PubMed ID: 8553569
[TBL] [Abstract][Full Text] [Related]
31. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.
Ives JA; Carr JA; Mendel DB; Tai CY; Lambkin R; Kelly L; Oxford JS; Hayden FG; Roberts NA
Antiviral Res; 2002 Aug; 55(2):307-17. PubMed ID: 12103431
[TBL] [Abstract][Full Text] [Related]
32. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
Govorkova EA; Leneva IA; Goloubeva OG; Bush K; Webster RG
Antimicrob Agents Chemother; 2001 Oct; 45(10):2723-32. PubMed ID: 11557461
[TBL] [Abstract][Full Text] [Related]
33. A novel means of identifying the neuraminidase type of currently circulating human A(H1) influenza viruses.
Hurt AC; Barr IG; Komadina N; Hampson AW
Virus Res; 2004 Jul; 103(1-2):79-83. PubMed ID: 15163493
[TBL] [Abstract][Full Text] [Related]
34. The neuraminidases of MDCK grown human influenza A(H3N2) viruses isolated since 1994 can demonstrate receptor binding.
Mohr PG; Deng YM; McKimm-Breschkin JL
Virol J; 2015 Apr; 12():67. PubMed ID: 25896455
[TBL] [Abstract][Full Text] [Related]
35. Accumulation of defective neuraminidase (NA) genes by influenza A viruses in the presence of NA inhibitors as a marker of reduced dependence on NA.
Nedyalkova MS; Hayden FG; Webster RG; Gubareva LV
J Infect Dis; 2002 Mar; 185(5):591-8. PubMed ID: 11865415
[TBL] [Abstract][Full Text] [Related]
36. Characterization of terminal sialic acid linkages on human thymocytes. Correlation between lectin-binding phenotype and sialyltransferase expression.
Baum LG; Derbin K; Perillo NL; Wu T; Pang M; Uittenbogaart C
J Biol Chem; 1996 May; 271(18):10793-9. PubMed ID: 8631891
[TBL] [Abstract][Full Text] [Related]
37. Influenza virus susceptibility and resistance to oseltamivir.
Aoki FY; Boivin G; Roberts N
Antivir Ther; 2007; 12(4 Pt B):603-16. PubMed ID: 17944268
[TBL] [Abstract][Full Text] [Related]
38. In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of hemagglutinin-pseudotyped viruses.
Su CY; Wang SY; Shie JJ; Jeng KS; Temperton NJ; Fang JM; Wong CH; Cheng YS
Antiviral Res; 2008 Sep; 79(3):199-205. PubMed ID: 18453004
[TBL] [Abstract][Full Text] [Related]
39. 6SLN-lipo PGA specifically catches (coats) human influenza virus and synergizes neuraminidase-targeting drugs for human influenza therapeutic potential.
Sriwilaijaroen N; Suzuki K; Takashita E; Hiramatsu H; Kanie O; Suzuki Y
J Antimicrob Chemother; 2015 Oct; 70(10):2797-809. PubMed ID: 26169554
[TBL] [Abstract][Full Text] [Related]
40.
Jeong JH; Choi WS; Antigua KJC; Choi YK; Govorkova EA; Webby RJ; Baek YH; Song MS
J Virol; 2020 Dec; 95(1):. PubMed ID: 33055248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
